U.S. Non-oncology Biopharmaceuticals Market Witnessing Four Fold Growth in 2019 Growing at CAGR of over 10.2% – Forecast to 2026
US Non-oncology Biopharmaceuticals Market- Insights
Biologics are very large, complex molecules or mixture of molecules that are derived from living entities such as microorganisms and plants or animal cells. A part of biologics, biopharmaceuticals are substances developed in living systems using biotechnology. Non-oncology biopharmaceuticals are drugs used for the treatment of diseases except cancer.
Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/2575
U.S. Non-oncology Biopharmaceuticals Market: Drivers
Approval and launch of new biopharmaceuticals for non-oncology diseases is expected to propel growth of the U.S. non-oncology biopharmaceuticals market over the forecast period. For instance, in September 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for its Emgality (galcanezumab-gnlm) 120 mg injection, for the preventive treatment of migraine in adults.
U.S. Non-oncology Biopharmaceuticals Market: Restraints
High cost of branded biologics is expected to hamper growth of the U.S. non-oncology biopharmaceuticals market. For instance, according to the report published by the Association for Accessible Medicines in 2018, the annual treatment with Humira costs US$ 38,000. Moreover, according to a report published by I-Mak.org, between 2012 and 2016, the average spending on Humira per person in U.S. increased from US$ 16,000 to US$ 33,000.
U.S. Non-oncology Biopharmaceuticals Market: Opportunities
Major blockbuster drugs are expected to lose patent protection, which is expected to offer lucrative opportunity for development of biosimilars. For instance, in 2017, Merck & Co., Inc. launched RENFLEXIS (infliximab-abda), a biosimilar of the originator biologic medicine Remicade (infliximab) by Janssen Biotech, Inc., in the U.S. at a wholesaler acquisition cost of US$ 753.39, representing a 35% discount to the current list price of Remicade.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2575
Development of IV/injectable biopharmaceuticals requires sophisticated infrastructure, skilled scientists, and significant resource investment. Such factors are expected to limit entry of new players in the market. Moreover, presence of major players in the market that have strong sales and marketing team is also expected to challenge entry of new players.
Physicians tend to not choose substitutes for well-established products, especially for diseases for which several products are available.
The U.S. non-oncology biopharmaceuticals market size was valued at US$ 116.0 Bn in 2018 and is expected to witness a CAGR of 10.2% during the forecast period (2018 – 2026).
Figure 1. U.S. Non-oncology Biopharmaceuticals Market Share (%), By Product Type, 2018-2026
Source: Coherent Market Insights Analysis (2018)
U.S. Non-oncology Biopharmaceuticals Market: Competitive Landscape
Major players operating in the U.S. non-oncology biopharmaceuticals market include, Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG, Amgen, Inc., Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Novo Nordisk A/S, GlaxoSmithKline plc., UCB Pharma, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd, AstraZeneca Plc, Mylan N.V., LEO Pharma A/S, Boehringer Ingelheim GmbH, Alexion Pharmaceuticals Inc., Merck & Co., Inc., Elusys Therapeutics, Inc., Swedish Orphan Biovitrum AB, Samsung Bioepis NL B.V., Biogen Inc., and Theratechnologies Inc.
Table 1. Revenue of Top Non-oncology Biopharmaceutical Brands in the U.S.
Source: Coherent Market Insights Analysis (2018)
U.S. Non-oncology Biopharmaceuticals Market: Key Developments
Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in July 2018, Amgen Inc. and UCB Inc. resubmitted the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk of fracture.
Similarly, in February 2018, Novartis announced that the U.S. Food and Drug Administration (FDA) approved a label update for its Cosentyx (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved for the treatment of moderate-to-severe plaque psoriasis.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/us-non-oncology-biopharmaceuticals-market-to-surpass-us-2530-bn-threshold-by-2026-1353
Major players in the market are also focused on adopting collaboration strategies to expand their product portfolio. For instance, in 2017, Sanofi S.A. and its vaccines business unit Sanofi Pasteur collaborated with MedImmune, the global biologics research and development arm of AstraZeneca Plc., for the development and commercialization of a monoclonal antibody, namely MEDI8897, for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants.About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire